PES-HORISONT-EU-PES Horisont Europa
Clinical validation of a new diagnostic test for Drug SEnsitivity Evaluation in ColoRectal Cancer (DSEE-CRC)
Currently, cancer treatment relies on poorly personalized drug therapies. About 80% of patients with advanced cancer are treated with chemotherapy, often to no avail, and drug and treatment costs continue to rise. These factors result in low quality of life for patients and high costs for healthc...